This article is more than 5 years old. Information may no longer be current.

Amniox releases amniotic membrane technology for orthopedic market

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Amniox Medical Inc. introduced its NEOX Grafts, amniotic membrane grafts intended for orthopedic and podiatric use, at the Annual Scientific Conference of the American College of Foot and Ankle Surgeons in San Antonio.

The NEOX products are amniotic membrane grafts preserved through a patented process called CRYOTEK, which maintains the innate biological potential of the membrane. While cryopreserved amniotic membrane is primarily used for ophthalmic indications, Amniox has introduced it for use in the orthopedic and podiatric markets.

“With over 100,000 human transplants behind Amniox, our unique wound and soft tissue management will soon be a standard in the orthopedic and podiatric industry,” Chris Fair, the founder, president and chief executive officer of Amniox, stated in the release.